Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma

NCT02631746 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02631746
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02631746 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
February 23, 2017
Completion date
July 31, 2019
Enrollment
3 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

acute adult t-cell leukemia/lymphoma, adult t-cell leukemia/lymphoma, chronic adult t-cell leukemia/lymphoma, htlv-1 infection, lymphomatous adult t-cell leukemia/lymphoma, smoldering adult t-cell leukemia/lymphoma